Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 5, 2013
GAINESVILLE, Fla. --- Researchers have discovered a way to make a blood thinner safer for about 40 percent of African-Americans taking the drug by linking a common gene variation to the dose.
These findings, published June 4 EDT in The Lancet, are the latest results from ongoing collaborative work by 42 researchers from 17 institutions in the International Warfarin Pharmacogenetics Consortium led by University of Florida Health researcher Julie A. Johnson, a distinguished professor of pharmacy and medicine and director of the UF Center for Pharmacogenomics.
A highly effective blood thinner taken by patients at risk for strokes caused by clotting, warfarin also contributes to nearly one-third of all hospital admissions for adverse drug events.